Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 6Recruiting 4Terminated 3Withdrawn 2Not yet recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Breast Neoplasms 21Lymphoma 18Lymphoma, Large B-Cell, Diffuse 15Leukemia, Myeloid, Acute 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 12Leukemia, Lymphocytic, Chronic, B-Cell 12Multiple Myeloma 11Burkitt Lymphoma 11Leukemia 10Lymphoma, Mantle-Cell 9Myelodysplastic Syndromes 8Melanoma 8Lymphoma, B-Cell, Marginal Zone 7Triple Negative Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Hodgkin Disease 6Carcinoma, Non-Small-Cell Lung 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Sarcoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Myeloid, Chronic-Phase 4

Interventions

Cisplatin 14pembrolizumab 8Radiotherapy 7Nivolumab 7Radiotherapy, Intensity-Modulated 5Cetuximab 5Carboplatin 5Fluorouracil 4durvalumab 3Radiosurgery 3Magnetic Resonance Spectroscopy 3Docetaxel 3fluoromisonidazole 2epacadostat 2Standard of Care 2Specimen Handling 2Photochemotherapy 2Paclitaxel 2Drug Therapy 2Cyclophosphamide 2Chemotherapy, Adjuvant 2Capecitabine 2C188-9 compound 2zimberelimab 1yeast-CEA vaccine 1vandetanib 1temoporfin 1talazoparib 1ruxolitinib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Squamous Cell Carcinoma of Head and Neck × Cyclophosphamide × Clear all
NCT03169764 2025-02-24

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

ImmunityBio, Inc.

Phase 1/2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03575234 2019-08-28

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Emory University

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡